Palonosetron hydrochloride

Product Name: Palonosetron hydrochloride
Form: Powder
Specification: 99%
MF: C19H25ClN2O
MW:332.87
Appearance: White Powder
CAS NO.:135729-62-3
Detection Method: HPLC
Sieve analysis: 100% pass 80 mesh
Shelf Life: Two years

Detailed Description

Palonosetron hydrochloride is a new type of high – selective and high affinity 5-ht3 receptor antagonist, which can block the presynaptic presynaptic 5-ht of the peripheral neurons in the peripheral neurons.The excitation of the receptor directly affects 5-HT in the central nervous system.The excitatory impulse of the receptor blocks the vagus nerve endings in the gut through the vagus nerve and stops the signal from passing to 5-ht.Receptor trigger zone, reducing the incidence of nausea and vomiting.Clinically, it is used to treat acute, delayed nausea and vomiting caused by moderate and severe vomiting chemotherapy.Due to its high efficacy, small side

Functions

Palonosetron hydrochloride is a new type of high – selective and high affinity 5-ht3 receptor antagonist, which can block the presynaptic presynaptic 5-ht of the peripheral neurons in the peripheral neurons.The excitation of the receptor directly affects 5-HT in the central nervous system.The excitatory impulse of the receptor blocks the vagus nerve endings in the gut through the vagus nerve and stops the signal from passing to 5-ht.Receptor trigger zone, reducing the incidence of nausea and vomiting.Clinically, it is used to treat acute, delayed nausea and vomiting caused by moderate and severe vomiting chemotherapy.Due to its high efficacy, small side effects, long half-life (about 40 h) and small dosage of medication, it is closely watched.
1,2,3, 4-tetrahydro-1-naphthalic acid was used as the starting material. It was broken up, amination, reduction, ring, and salt.
Clinical studies have shown that palonosetron can be used safely in conjunction with corticosteroid, analgesics, anticonvulsants, anticonvulsants and anticholinergic drugs.
The study of mouse tumor model showed that palonosetron would not inhibit the anticancer activity of the five chemotherapy drugs (cisplatin, cyclophosphamide, amycin, adriamycin, and mitomycin C).